Havana, April 25 (RHC)-- The Cuban medication Heberprot-P to fight diabetic foot ulcers was registered by Mexico's Federal Commission for Protection against Health Risks, the authority in charge of drug registration in the country.

The Cuban pharmaceutical is administered by injections that step up the healing of deep ulcers caused by diabetes, a major cause of lower limb amputation in Mexico.

The medication, which was developed by the Havana-based Genetic Engineering and Biotechnology Center, reduces the risk of complications such as gangrene or infections.

The registration of the pharmaceutical was announced in Havana at the first meeting of the Mexico-Cuba Health Cooperation Group with the presence of Mexican Health Minister Jose Narros.

During the meeting, the two sides agreed to look at new lines of research on diseases with strong impact on the population, such as cancer, hypertension, as well as mental and genetic disorders.